GlassScriptPhysician profile
David Raj Bass
NPI 1083674691
$5,474.27
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $744 · 2020: $617 · 2021: $1,382 · 2022: $1,264 · 2023: $1,267 · 2024: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,466.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,515.36 | 2019-2024 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,243.15 | 2019-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $466.69 | 2019-2024 | Entyvio |
| Celgene Corporation | $262.77 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $243.33 | 2019-2023 | Stelara, Simponi, Remicade |
| Redhill Biopharma INC. | $218.97 | 2020-2023 | Talicia |
| Pfizer INC. | $159.09 | 2019-2023 | |
| Balt USA, LLC | $150.82 | 2022 | |
| Daiichi Sankyo INC. | $138.56 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $126.67 | 2021-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $121.32 | 2020-2023 | Linzess |
| Qol Medical, LLC | $119.88 | 2019-2024 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $114.98 | 2020-2021 | |
| Ardelyx, INC. | $110.39 | 2022-2023 | Ibsrela |
| Lilly USA, LLC | $76.63 | 2023-2024 | Omvoh |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $59.50 | 2019-2020 | |
| Shionogi INC | $58.46 | 2019-2020 | |
| Braintree Laboratories, INC. | $52.80 | 2020-2023 | Suflave |
| Nestle Healthcare Nutrition INC. | $42.68 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $40.39 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $34.98 | 2022 | |
| Intuitive Surgical, INC. | $23.64 | 2019 | |
| Tersera Therapeutics LLC | $21.02 | 2021 | |
| Pharmacosmos Therapeutics INC. | $20.19 | 2020 | |
| Alexion Pharmaceuticals, INC. | $17.67 | 2019 | |
| Covidien LP | $13.40 | 2019 | |
| Ethicon US, LLC | $12.16 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $8.77 | 2021-2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$29,815.14 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.